開発中のRNA治療は 230%以上の利益の可能性がある 強力な"買い"評価を得ています Avidity Biosciences, developing RNA treatments, receives strong "buy" rating with potential for over 230% gain.

NASDAQに記載された生物医薬品会社アビティバイオ科学社は,アナリストから強い"Buy"評価を採択し,同社の現在価格から約65.59ドル,潜在的に230.69%の逆転を遂げた. Avidity Biosciences, a biopharmaceutical firm listed on NASDAQ, has garnered a strong "buy" rating from analysts, with a consensus target price of $65.59 and a potential upside of 230.69% from its current price. 同社はRNA治療薬を開発しており,その中には第1型筋縮症の主要製品も含まれ,第2段階の試験段階にある. The company is developing RNA therapeutics, including its lead product for myotonic dystrophy type 1, which is in phase 1/2 trials. 負の純利益と 資本収益率にもかかわらず Avidityの市場キャピタルは 35億ドルです Despite a negative net margin and return on equity, Avidity's market cap stands at $3.50 billion.